Familial Hypercholesterolaemia: Implementing a systems approach to detection and management – Public Health England

This guide provides further information on the recently updated NICE Guideline (CG71) Familial Hypercholesterolaemia: identification and management. It includes: a summary of recommendations from the recent update of the document an outline of national and European policy documents best practice case

Mechanical thrombectomy devices for acute ischaemic stroke: Medtech innovation briefing [MIB153] – NICE

Thetechnologies described in this briefing are 21 mechanical thrombectomy devices of 2 types: stent retrievers and aspiration catheters. They are used to remove blood clots from a main cerebral artery to restore blood flow after acute ischaemic stroke. The innovative aspects are that

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing: Interventional procedures guidance [IPG622] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures [IPG623] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound to promote healing

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing: Interventional procedures guidance [IPG621] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534] – NICE

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults. Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other

Endometriosis: Quality standard [QS172] – NICE

This quality standard covers diagnosing and managing endometriosis in women, including young women aged 17 and under. It describes high-quality care in priority areas for improvement.

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA537] – NICE

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE’s technology appraisal

Intermediate care including reablement: Quality standard [QS173] – NICE

This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid

Transaxial interbody lumbosacral fusion for severe chronic low back pain: Interventional procedures guidance [IPG620] – NICE

Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults. This involves removing a damaged disc through a small cut at the base of the spine, and replacing it with an artificial implant. This guidance replaces NICE interventional

Superior capsular augmentation for massive rotator cuff tears: Interventional procedures guidance [IPG619] – NICE

Evidence-based recommendations on superior capsular augmentation for massive rotator cuff tears in adults. This involves using a graft to stabilise the shoulder joint, reduce pain and improve shoulder function.

Cenegermin for treating neurotrophic keratitis: Technology appraisal guidance [TA532] – NICE

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults.

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: Technology appraisal guidance [TA531] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.

Early and locally advanced breast cancer: diagnosis and management: NICE guideline [NG101] – NICE

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast

National Early Warning Score (NEWS) 2 Standardising the assessment of acute-illness severity in the NHS: Updated report of a working party – Royal College of Physicians

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the

NICE Bites May 2018: No 107: Sore throat (acute); antimicrobial prescribing NICE NG84: 2018: Otitis Media (acute); antimicrobial prescribing NICE NG91; 2018 – NICE

Prescribing bulletin published by North West Medicines Information centre which summarises key recommendations from NICE guidance. NICE Bites No 107 May 2018 includes two topics, covering assessment, treatment and management, general advice, self-care advice, ‘no prescription’ advice, ‘back-up’ prescription advice,

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma: Technology appraisal guidance [TA524] – NICE

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446.  

Arsenic trioxide for treating acute promyelocytic leukaemia: Technology appraisal guidance [TA526] – NICE

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.  

External review of a sample of Local Supervising Authority (England) Supervisory Investigations into the standard of midwifery practice in Maternity Serious Incidents that were conducted between 1 April and 31 December 2016 – NHS England

An independent review report commissioned by NHS England in response to two previous commissions relating to the quality of midwifery supervision. Although statutory supervision has been removed and replaced with a new model of supervision, A-EQUIP, this review document provides